156 related articles for article (PubMed ID: 20594593)
1. Evaluation of comorbidities at diagnosis predicts outcome in myelodysplastic syndrome patients.
Breccia M; Federico V; Latagliata R; Mercanti C; D'Elia GM; Cannella L; Loglisci G; Salaroli A; Santopietro M; Alimena G
Leuk Res; 2011 Feb; 35(2):159-62. PubMed ID: 20594593
[TBL] [Abstract][Full Text] [Related]
2. Comorbidities and FLT3-ITD abnormalities as independent prognostic indicators of survival in elderly acute myeloid leukaemia patients.
Breccia M; Frustaci AM; Cannella L; Stefanizzi C; Latagliata R; Cartoni C; Diverio D; Guarini A; Nanni M; Rago A; Cimino G; Alimena G
Hematol Oncol; 2009 Sep; 27(3):148-53. PubMed ID: 19274612
[TBL] [Abstract][Full Text] [Related]
3. Comparison of two pretransplant predictive models and a flexible HCT-CI using different cut off points to determine low-, intermediate-, and high-risk groups: the flexible HCT-CI Is the best predictor of NRM and OS in a population of patients undergoing allo-RIC.
Barba P; Piñana JL; Martino R; Valcárcel D; Amorós A; Sureda A; Briones J; Delgado J; Brunet S; Sierra J
Biol Blood Marrow Transplant; 2010 Mar; 16(3):413-20. PubMed ID: 19922807
[TBL] [Abstract][Full Text] [Related]
4. Comorbidity predicts survival in myelodysplastic syndromes or secondary acute myeloid leukaemia after allogeneic stem cell transplantation.
Boehm A; Sperr WR; Leitner G; Worel N; Oehler L; Jaeger E; Mitterbauer M; Haas OA; Valent P; Kalhs P; Rabitsch W
Eur J Clin Invest; 2008 Dec; 38(12):945-52. PubMed ID: 19021720
[TBL] [Abstract][Full Text] [Related]
5. Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome.
Della Porta MG; Malcovati L; Strupp C; Ambaglio I; Kuendgen A; Zipperer E; Travaglino E; Invernizzi R; Pascutto C; Lazzarino M; Germing U; Cazzola M
Haematologica; 2011 Mar; 96(3):441-9. PubMed ID: 21134982
[TBL] [Abstract][Full Text] [Related]
6. Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome: prognostic significance of pre-transplant IPSS score and comorbidity.
Lee JH; Lee JH; Lim SN; Kim DY; Kim SH; Lee YS; Kang YA; Kang SI; Jeon MJ; Seol M; Seo EJ; Chi HS; Park CJ; Jang S; Yun SC; Lee KH
Bone Marrow Transplant; 2010 Mar; 45(3):450-7. PubMed ID: 19668236
[TBL] [Abstract][Full Text] [Related]
7. Age and comorbidities deeply impact on clinical outcome of patients with myelodysplastic syndromes.
Balleari E; Salvetti C; Del Corso L; Filiberti R; Bacigalupo A; Bellodi A; Beltrami G; Bergamaschi M; Berisso G; Calzamiglia T; Carella AM; Cavalleri M; Da Col A; Favorini S; Forni GL; Goretti R; Miglino M; Mitscheuning L; Molinari E; Racchi O; Scudeletti M; Tassara R; Gobbi M; Lemoli R; Clavio M
Leuk Res; 2015 Aug; 39(8):846-52. PubMed ID: 26145790
[TBL] [Abstract][Full Text] [Related]
8. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
[TBL] [Abstract][Full Text] [Related]
9. Myeloablative hematopoietic stem cell transplantation for myelodysplastic syndrome in patients younger than 55 years: impact of comorbidity and disease burden on the long-term outcome.
Kanamori H; Enaka M; Ito S; Motohashi K; Hagihara M; Oshima R; Sakai R; Fujisawa S; Tanaka M; Fujimaki K; Fujita H; Ishigatsubo Y; Maruta A
Int J Lab Hematol; 2010 Apr; 32(2):222-9. PubMed ID: 19573175
[TBL] [Abstract][Full Text] [Related]
10. Clustering of comorbidities is related to age and sex and impacts clinical outcome in myelodysplastic syndromes.
Bammer C; Sperr WR; Kemmler G; Wimazal F; Nösslinger T; Schönmetzler A; Krieger O; Pfeilstöcker M; Valent P; Stauder R
J Geriatr Oncol; 2014 Jul; 5(3):299-306. PubMed ID: 24636334
[TBL] [Abstract][Full Text] [Related]
11. Hemoglobin level, chronic kidney disease, and the risks of death and hospitalization in adults with chronic heart failure: the Anemia in Chronic Heart Failure: Outcomes and Resource Utilization (ANCHOR) Study.
Go AS; Yang J; Ackerson LM; Lepper K; Robbins S; Massie BM; Shlipak MG
Circulation; 2006 Jun; 113(23):2713-23. PubMed ID: 16754803
[TBL] [Abstract][Full Text] [Related]
12. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.
Hershman D; Neugut AI; Jacobson JS; Wang J; Tsai WY; McBride R; Bennett CL; Grann VR
J Natl Cancer Inst; 2007 Feb; 99(3):196-205. PubMed ID: 17284714
[TBL] [Abstract][Full Text] [Related]
13. Differential prognostic impact of pretransplant comorbidity on transplant outcomes by disease status and time from transplant: a single Japanese transplant centre study.
Kataoka K; Nannya Y; Ueda K; Kumano K; Takahashi T; Kurokawa M
Bone Marrow Transplant; 2010 Mar; 45(3):513-20. PubMed ID: 19684632
[TBL] [Abstract][Full Text] [Related]
14. The incidence and impact of comorbidity diagnosed after the onset of head and neck cancer.
Yung KC; Piccirillo JF
Arch Otolaryngol Head Neck Surg; 2008 Oct; 134(10):1045-9. PubMed ID: 18936348
[TBL] [Abstract][Full Text] [Related]
15. The influence of comorbidities, age, and performance status on the prognosis and treatment of patients with metastatic carcinomas of unknown primary site: a population-based study.
Seve P; Sawyer M; Hanson J; Broussolle C; Dumontet C; Mackey JR
Cancer; 2006 May; 106(9):2058-66. PubMed ID: 16583433
[TBL] [Abstract][Full Text] [Related]
16. Proper treatment selection may improve survival in patients with clinical early-stage nonsmall cell lung cancer.
Birim O; Kappetein AP; Goorden T; van Klaveren RJ; Bogers AJ
Ann Thorac Surg; 2005 Sep; 80(3):1021-6. PubMed ID: 16122477
[TBL] [Abstract][Full Text] [Related]
17. [Influence of comorbidities on decision caring of malignant haematological diseases].
Najman A; Andre K; Gorin NC
Bull Cancer; 2009 May; 96(5):563-70. PubMed ID: 19467987
[TBL] [Abstract][Full Text] [Related]
18. Arsenic trioxide in patients with myelodysplastic syndromes: a phase II multicenter study.
Vey N; Bosly A; Guerci A; Feremans W; Dombret H; Dreyfus F; Bowen D; Burnett A; Dennis M; Ribrag V; Casadevall N; Legros L; Fenaux P
J Clin Oncol; 2006 Jun; 24(16):2465-71. PubMed ID: 16651646
[TBL] [Abstract][Full Text] [Related]
19. The evolution of hematopoietic SCT in myelodysplastic syndrome.
Kindwall-Keller T; Isola LM
Bone Marrow Transplant; 2009 Apr; 43(8):597-609. PubMed ID: 19252532
[TBL] [Abstract][Full Text] [Related]
20. Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes.
Schiller GJ; Slack J; Hainsworth JD; Mason J; Saleh M; Rizzieri D; Douer D; List AF
J Clin Oncol; 2006 Jun; 24(16):2456-64. PubMed ID: 16651647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]